Aclaris Secures FDA Fast Track for Lichen Planus Drug Modzatinib — Aclaris Therapeutics, Inc.

Event summary

Aclaris Therapeutics' modzatinib (ATI-2138) receives FDA Fast Track Designation for moderate to severe lichen planus (LP).
Phase 2b trial initiation expected in Q4 2026.
Fast Track designation allows for rolling NDA review and potential Priority Review eligibility.

The big picture

Aclaris Therapeutics is positioning itself in the competitive immuno-inflammatory disease space with a focus on unmet medical needs. The Fast Track designation for modzatinib underscores the FDA's recognition of the seriousness of lichen planus and the potential of this novel therapy to address it. This strategic move could differentiate Aclaris from competitors, particularly if the Phase 2b trial yields positive results.

What we're watching

Regulatory Advantage: How the Fast Track designation will accelerate modzatinib's development timeline and reduce regulatory hurdles.
Clinical Execution: Whether Aclaris can successfully initiate and complete the Phase 2b trial as planned in Q4 2026.
Market Opportunity: The pace at which modzatinib could capture market share if approved, given the lack of current therapies for LP.